{"news_desk": "OpEd", "print_page": "23", "section_name": "Opinion", "subsection_name": null, "document_type": "article", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-thumbWide.jpg"}, {"height": 438, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "438", "xlarge": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2015/01/06/opinion/06HinkesJones/06HinkesJones-thumbStandard.jpg"}], "abstract": "Op-Ed article by journalist Llewellyn Hinkes-Jones opposes the rise of so-called 'venture philanthropy' in the pharmaceutical industry; calls it yet another term for privatizing scientific research; holds trend introduces tax-exempt loophole, allowing organizations to develop drugs on publicly funded research and then sell results to private industry; calls for increased funding to the National Institutes of Health, and for rule that would prevent venture philanthropists from obtaining exclusive patent rights.", "type_of_material": "Op-Ed", "word_count": "748", "lead_paragraph": "Venture philanthropy risks benefiting companies, not patients.", "pub_date": "2015-01-06T00:00:00Z", "_id": "54ab34ab38f0d83eda14cc57", "byline": {"contributor": "", "original": "By LLEWELLYN HINKES-JONES", "person": [{"rank": 1, "role": "reported", "firstname": "Llewellyn", "organization": "", "lastname": "HINKES-JONES"}]}, "source": "The New York Times", "snippet": "Venture philanthropy risks benefiting companies, not patients.", "web_url": "http://www.nytimes.com/2015/01/06/opinion/stop-subsidizing-big-pharma.html", "slideshow_credits": null, "blog": [], "keywords": [{"rank": "1", "is_major": "Y", "value": "Philanthropy", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "National Institutes of Health", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Tax Credits, Deductions and Exemptions", "name": "subject"}, {"rank": "5", "is_major": "Y", "value": "Research", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Corporate Taxes", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Biotechnology and Bioengineering", "name": "subject"}, {"rank": "8", "is_major": "N", "value": "Cystic Fibrosis Foundation", "name": "organizations"}, {"rank": "9", "is_major": "N", "value": "Vertex Pharmaceuticals Inc", "name": "organizations"}, {"rank": "10", "is_major": "N", "value": "Royalties", "name": "subject"}], "headline": {"main": "Stop Subsidizing Big Pharma", "content_kicker": "Op-Ed Contributor", "print_headline": "Stop Subsidizing Big Pharma", "kicker": "Op-Ed Contributor"}}